ions.bio

ions.bio

Munich, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ions.bio is a Munich-based biomarker solutions company offering a full-stack service from clinical sample collection to AI-powered data analysis. The company's core strength lies in its integrated platform combining automated laboratory processes, mass spectrometry-based proteomics/lipidomics/metabolomics, and proprietary bioinformatics software to de-risk and accelerate biomarker development. With a scientifically prolific founding team and a focus on generating validated, assay-ready biomarkers, ions.bio positions itself as a strategic partner for pharmaceutical and diagnostic companies seeking to leverage next-generation biomarkers.

Drug DeliveryBiologics

Technology Platform

Integrated biomarker discovery platform combining clinical sample collection, mass spectrometry-based multi-omics (proteomics, lipidomics, metabolomics), and proprietary AI-driven data analysis/ bioinformatics software with a proprietary sample database.

Opportunities

The growing demand for precision medicine and companion diagnostics creates a large market for robust biomarker services.
The trend of pharma outsourcing specialized R&D functions and the increasing adoption of multi-omics in clinical trials present significant growth opportunities.
The company's ability to deliver validated, assay-ready biomarkers positions it as a high-value partner to accelerate drug development pipelines.

Risk Factors

Revenue is dependent on securing project-based contracts in a competitive market with large CROs.
The long and uncertain path to clinical validation and regulatory approval for biomarkers poses an indirect risk to the value of its services.
Intellectual property ownership in collaborative projects can be complex and contentious.

Competitive Landscape

ions.bio competes with large, diversified contract research organizations (CROs like LabCorp, IQVIA) that offer omics services, specialized proteomics/metabolomics service providers, and diagnostic companies with internal discovery platforms. Its differentiation lies in its end-to-end integration, proprietary AI software, strong focus on sample quality and validation, and the deep academic expertise of its founding team.